Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/52382
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Effect of rosiglitazone on peroxisome proliferator-activated receptor γ gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction
Other Titles: Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction
Author: Mallon, P.
Sedwell, R.
Rogers, G.
Nolan, D.
Unemori, P.
Hoy, J.
Samaras, K.
Kelleher, A.
Emery, S.
Cooper, D.
Carr, A.
Citation: Journal of Infectious Diseases, 2008; 198(12):1794-1803
Publisher: Univ Chicago Press
Issue Date: 2008
ISSN: 0022-1899
1537-6613
Statement of
Responsibility: 
Patrick W. G. Mallon, Rebecca Sedwell, Gary Rogers, David Nolan, Patrick Unemori, Jennifer Hoy, Katherine Samaras, Anthony Kelleher, Sean Emery, David A. Cooper, and Andrew Carr for the Rosey Investigators
Abstract: Background. Treatment of human immunodeficiency virus (HIV)–1 with thymidine-analogue nucleoside reverse-transcriptase inhibitors (tNRTIs) causes lipoatrophy, mitochondrial toxicity, and lower adipose tissue expression of peroxisome proliferator-activated receptor (PPAR [PPARG gene]) . Rosiglitazone (RSG), a PPAR agonist, improves congenital lipoatrophy but not HIV lipoatrophy. Methods. Serial fat biopsies were taken from HIV-infected, lipoatrophic men randomized to receive RSG or placebo for 48 weeks. Adipose tissue mitochondrial and nuclear gene expression and mitochondrial DNA content were quantified by real-time polymerase chain reaction. Nonparametric analyses were applied. Results. Subjects receiving tNRTI-containing antiretroviral therapy had lower baseline mitochondrial RNA expression and DNA content. In subjects receiving tNRTIs, exposure to RSG did not affect PPARG expression at either week 2 or 48. At week 2, RSG increased PPARG expression only in subjects not treated with tNRTIs, whereas at week 48, increased PPARG expression was observed in subjects not treated with tNRTIs, regardless of RSG use. Similar findings were observed for the PPARG-responsive gene fatty acid– binding protein 4. Changes in PPARG expression were associated with increases in limb fat mass. Conclusions. These data suggest that in HIV-infected, lipoatrophic men, adipose PPARG expression and function are dependent on intact mitochondrial function. These data support a direct link between mitochondrial toxicity and adipose tissue PPARG expression and help explain the poor clinical response to RSG observed in clinical trials.
Keywords: Rosey Investigators; Adipose Tissue; Mitochondria; Humans; HIV-Associated Lipodystrophy Syndrome; Thiazolidinediones; Heat-Shock Proteins; PPAR gamma; Transcription Factors; DNA, Mitochondrial; RNA; Hypoglycemic Agents; Anti-HIV Agents; Drug Administration Schedule; Gene Expression Regulation; Body Composition; Adult; Female; Male; Fatty Acid-Binding Proteins; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Rosiglitazone; RNA, Mitochondrial
RMID: 0020084035
DOI: 10.1086/593179
Appears in Collections:General Practice publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.